This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 2 EPO patents. Top assignees: Centre National De La Recherche Scientifique, National Institute of Health and Medical Research, The University of Nantes. Active years: 2013.
Company Filing History:
1 out of 5,383 
1 out of 1,853 
1 out of 156 
Years Active: 2013
Title: Marc Padrines: Innovator in Hydroxy-bisphosphonic Acid Derivatives
Introduction
Marc Padrines is a notable inventor based in Carquefou, France. He has made significant contributions to the field of chemistry, particularly in the development of hydroxy-bisphosphonic acid derivatives. His work focuses on creating compounds that target bone tissue, which has important implications for therapeutic and diagnostic applications.
Latest Patents
Marc Padrines holds a patent for "Hydroxy-bisphosphonic acid derivatives as vector targeting bone tissue." This invention relates to hydroxy-bisphosphonic acid derivatives that correspond to a specific general formula. The derivatives are designed to include various components, such as linear or branched alkyl groups and residues of therapeutic or diagnostic interest. The patent also covers the methods for preparing these derivatives and their potential uses in medicine.
Career Highlights
Throughout his career, Marc Padrines has worked with esteemed institutions, including the University of Nantes and the National Institute of Health and Medical Research. His research has contributed to advancements in the understanding and application of bisphosphonic acid derivatives in medical science.
Collaborations
Marc has collaborated with notable colleagues, including Dominique Heymann and Francoise Redini. These partnerships have enhanced his research and contributed to the development of innovative solutions in his field.
Conclusion
Marc Padrines is a distinguished inventor whose work on hydroxy-bisphosphonic acid derivatives has the potential to impact medical treatments significantly. His contributions to the field of chemistry and collaboration with leading institutions highlight his commitment to innovation.